Shire PLC (SHPG) Holdings Trimmed by Leavell Investment Management Inc.

Leavell Investment Management Inc. reduced its stake in shares of Shire PLC (NASDAQ:SHPG) by 26.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,938 shares of the biopharmaceutical company’s stock after selling 1,033 shares during the period. Leavell Investment Management Inc.’s holdings in Shire were worth $456,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the company. Quadrant Capital Group LLC lifted its position in shares of Shire by 3.7% in the 2nd quarter. Quadrant Capital Group LLC now owns 1,839 shares of the biopharmaceutical company’s stock worth $280,000 after buying an additional 66 shares during the last quarter. Bayesian Capital Management LP lifted its position in shares of Shire by 3.9% in the 2nd quarter. Bayesian Capital Management LP now owns 3,947 shares of the biopharmaceutical company’s stock worth $652,000 after buying an additional 147 shares during the last quarter. ETRADE Capital Management LLC lifted its position in shares of Shire by 2.6% in the 2nd quarter. ETRADE Capital Management LLC now owns 6,218 shares of the biopharmaceutical company’s stock worth $1,028,000 after buying an additional 160 shares during the last quarter. L & S Advisors Inc lifted its position in shares of Shire by 6.3% in the 2nd quarter. L & S Advisors Inc now owns 2,886 shares of the biopharmaceutical company’s stock worth $477,000 after buying an additional 171 shares during the last quarter. Finally, Roberts Glore & Co. Inc. IL lifted its position in shares of Shire by 10.2% in the 2nd quarter. Roberts Glore & Co. Inc. IL now owns 2,218 shares of the biopharmaceutical company’s stock worth $367,000 after buying an additional 206 shares during the last quarter. Institutional investors own 20.19% of the company’s stock.

SHPG has been the topic of a number of recent research reports. ValuEngine upgraded shares of Shire from a “hold” rating to a “buy” rating in a research report on Thursday, October 26th. Stifel Nicolaus restated a “buy” rating and issued a $245.00 price target on shares of Shire in a research report on Sunday, October 8th. Royal Bank of Canada restated a “buy” rating and issued a $213.00 price target on shares of Shire in a research report on Monday, October 2nd. FBR & Co initiated coverage on shares of Shire in a research report on Thursday, October 19th. They issued a “buy” rating and a $201.00 price target on the stock. Finally, Cantor Fitzgerald set a $222.00 price target on shares of Shire and gave the stock a “buy” rating in a research report on Thursday, November 16th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and eight have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $212.18.

Shire PLC (SHPG) opened at $147.55 on Friday. The company has a market cap of $44,642.92, a PE ratio of 10.21, a price-to-earnings-growth ratio of 0.80 and a beta of 1.60. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.52 and a current ratio of 0.98. Shire PLC has a 52 week low of $137.17 and a 52 week high of $192.15.

Shire (NASDAQ:SHPG) last released its earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.64 by $0.17. The firm had revenue of $3.70 billion for the quarter. Shire had a net margin of 10.95% and a return on equity of 14.41%. The firm’s quarterly revenue was up 7.1% on a year-over-year basis. During the same period in the previous year, the business posted $3.17 EPS. equities research analysts forecast that Shire PLC will post 15 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Shire PLC (SHPG) Holdings Trimmed by Leavell Investment Management Inc.” was published by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://www.com-unik.info/2018/01/13/shire-plc-shpg-holdings-trimmed-by-leavell-investment-management-inc.html.

Shire Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).

Institutional Ownership by Quarter for Shire (NASDAQ:SHPG)

What are top analysts saying about Shire? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Shire and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit